Medicare Advantage与传统Medicare中低价值肿瘤治疗的使用比较
该研究利用美国全国Medicare数据,回顾性分析2016至2021年新诊断癌症且存在低价值治疗风险的受益人,比较Medicare Advantage(MA)与传统Medicare(TM)中低价值肿瘤治疗的使用情况。结果显示,MA中任何低价值肿瘤治疗的使用率较TM低1.7个百分点(34.2% vs 35.9%;P < .001),且不同大型MA保险公司间差异程度中等。
要点
- MA中任何低价值肿瘤治疗使用率较TM低1.7个百分点(34.2% vs 35.9%;P < .001)。
- MA在低危化疗患者GCSF使用、CSPC地舒单抗、乳腺癌或肺癌白蛋白紫杉醇、卵巢癌加用贝伐珠单抗及有生物类似药替代品的生物制品上均低于TM。
- 品牌药使用在MA与TM间无显著差异,不同大型MA保险公司间低价值治疗使用差异程度中等。
核心结论
- MA中低价值肿瘤治疗的使用率低于TM,且不同大型MA保险公司间差异程度中等。
- 原文结论提出需要努力确定有效策略以减少低价值肿瘤治疗的使用。
研究设计与样本
- 研究类型为基于美国全国Medicare数据的回顾性分析。
- 研究对象为2016年至2021年间新诊断癌症且存在接受低价值治疗风险的受益人。
- 低价值治疗包括:低危化疗患者使用粒细胞集落刺激因子(GCSF)、去势敏感性前列腺癌(CSPC)使用地舒单抗、乳腺癌或肺癌以白蛋白紫杉醇替代紫杉醇、卵巢癌在卡铂联合紫杉醇基础上加用贝伐珠单抗、以及已有仿制药或生物类似药替代品的品牌药或生物制品。
主要发现
- MA中任何低价值肿瘤治疗使用率较TM低1.7个百分点(34.2% vs 35.9%;P < .001)。
- 低危化疗患者GCSF使用率MA低于TM(7.3% vs 8.9%;P < .001)。
- CSPC地舒单抗使用率MA低于TM(26.4% vs 33.1%;P < .001)。
- 乳腺癌或肺癌白蛋白紫杉醇使用率MA低于TM(7.9% vs 8.7%;P < .001)。
- 卵巢癌加用贝伐珠单抗比例MA低于TM(8.3% vs 10.5%;P < .001);有生物类似药替代品的生物制品使用率MA低于TM(66.8% vs 68.5%;P < .001)。
关键数值与推荐
- 任何低价值肿瘤治疗:MA 34.2% vs TM 35.9%(P < .001)。
- 低危化疗患者GCSF:MA 7.3% vs TM 8.9%(P < .001)。
- CSPC地舒单抗:MA 26.4% vs TM 33.1%(P < .001)。
- 乳腺癌或肺癌白蛋白紫杉醇:MA 7.9% vs TM 8.7%(P < .001)。
- 卵巢癌加用贝伐珠单抗:MA 8.3% vs TM 10.5%(P < .001);有生物类似药替代品的生物制品:MA 66.8% vs TM 68.5%(P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Medicare Advantage (MA) provides beneficiaries an option to receive Medicare benefits from private plans. Although MA covers over half of the Medicare population, limited information exists about how utilization of cancer treatments in MA differs from traditional Medicare (TM). We compared use of low-value cancer treatments between MA and TM and analyzed variation in use of low-value cancer treatments across large MA insurers. METHODS: Using national Medicare data, we performed retrospective analyses of beneficiaries who had a new cancer diagnosis between 2016 and 2021 and who were at risk of receiving a low-value treatment: granulocyte-colony stimulating factors (GCSFs) for patients receiving low-risk chemotherapy, denosumab for castration-sensitive prostate cancer (CSPC), nab-paclitaxel instead of paclitaxel for breast or lung cancers, adding bevacizumab to carboplatin plus paclitaxel for ovarian cancer, and branded drugs or biologics for which generic or biosimilar versions existed. RESULTS: Use of any low-value cancer treatment was 1.7 percentage points lower in MA than in TM (34.2% v 35.9%; P < .001). MA had lower utilization rates than TM for GCSF among patients receiving low-risk chemotherapy (7.3% v 8.9%; P < .001), denosumab for CSPC (26.4% v 33.1%; P < .001), nab-paclitaxel for breast or lung cancer (7.9% v 8.7%; P < .001), addition of bevacizumab for ovarian cancer (8.3% v 10.5%; P < .001), and biologics with biosimilar alternatives (66.8% v 68.5%; P < .001). Use of branded drugs did not significantly differ between MA and TM. The differences in use of low-value cancer treatments from TM varied moderately across large MA insurers. CONCLUSION: MA has lower use of low-value cancer treatments than TM, with varying degrees across large MA insurers. Efforts are needed to identify effective strategies to reduce use of low-value cancer treatments.
引用
- Jung J, Carlin C, Feldman R, et al. Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare. J Clin Oncol. 2025. PMID: 40448575. doi:10.1200/JCO-24-01907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。